NCT06399029View on ClinicalTrials.gov

Topical Ruxolitinib Evaluation in Immune-related Lichenoid Skin-Toxicities

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2025

Conditions
ExanthemaLichenoid Skin Rashes Under Anti-PD1 Tumor Therapy
Interventions
DRUG

Ruxolitinib Topical Cream

Ruxolitinib cream will be applied topically twice daily on up to 20% of the body surface over 12 weeks in patients with lichenoid skin toxicity under anti PD1 treatment.

Sponsors

Collaborators (1)

Incyte Corporation
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

lead

University of Zurich

OTHER